New drug trial aims to protect kids from debilitating neurological attacks

NCT ID NCT05346354

Recruiting now Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the drug ravulizumab can safely prevent relapses in children and adolescents with a rare autoimmune disorder called NMOSD, which attacks the spinal cord and optic nerves. The trial will follow 12 participants for about a year to see if the treatment reduces the frequency of disease flare-ups and improves disability scores. Ravulizumab works by blocking part of the immune system that causes damage in NMOSD.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Research Site
RECRUITING

Miami, Florida, 33136, United States
Research Site
RECRUITING

Boston, Massachusetts, 02114, United States
Research Site
WITHDRAWN

St Louis, Missouri, 63110, United States
Research Site
RECRUITING

Durham, North Carolina, 27705, United States
Research Site
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Research Site
RECRUITING

Edmonton, Alberta, T6G 1C9, Canada
Research Site
RECRUITING

Toronto, Ontario, M5G 1X8, Canada
Research Site
RECRUITING

Montreal, Quebec, H3T1C5, Canada
Research Site
RECRUITING

Le Kremlin-Bicêtre, 94270, France
Research Site
RECRUITING

Marseille, 13005, France
Research Site
RECRUITING

Montpellier, 34295, France
Research Site
WITHDRAWN

Bochum, 44791, Germany
Research Site
WITHDRAWN

Giessen, 35392, Germany
Research Site
WITHDRAWN

Catania, 95123, Italy
Research Site
RECRUITING

Chieti, 66013, Italy
Research Site
RECRUITING

Gallarate, 21013, Italy
Research Site
RECRUITING

Roma, 00165, Italy
Research Site
RECRUITING

Yokohama, 232-0024, Japan
Research Site
RECRUITING

Goyang-si, 10408, South Korea
Research Site
RECRUITING

Esplugues de Llobregat, 8950, Spain

Conditions

Explore the condition pages connected to this study.

NEUROMYELITIS OPTICA SPECTRUM DISORDER